Stockreport

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]

Acrivon Therapeutics, Inc.  (ACRV) 
PDF Acrivon Therapeutics, Inc. (ACRV) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates - [Read more]